electroCore (NASDAQ:ECOR) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS

electroCore (NASDAQ:ECOR) posted its quarterly earnings results on Wednesday. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.14, FiscalAI reports. The business had revenue of $9.69 million for the quarter, compared to analyst estimates of $10.93 million.

Here are the key takeaways from electroCore’s conference call:

• electroCore reported record third-quarter net sales of $9.7 million, up 12% year over year, with gross margin expanding to 88.5%. Adjusted EBITDA loss narrowed to a company-low $700,000, although GAAP results included a $400,000 settlement gain and a $100,000 tax benefit.
• The company lowered its 2026 revenue outlook to $39 million–$42 million, saying sales-force changes delayed the acceleration it had expected in the second half. Management now anticipates 30%–40% revenue growth in 2027 and targets its first positive Adjusted EBITDA quarter by year-end 2027, both dependent on execution.
• Management cited early gains from its commercial overhaul: newer representatives generated about 30% more monthly VA revenue than the territories did before, and VA new-patient orders rose 21% year over year. Refill revenue reached a company high, while the national refill rate was 42% through September, below the company’s goal of more than 70%.
• electroCore filed an FDA 510(k) submission for Quell to treat chemotherapy-induced peripheral neuropathy (CIPN), a potential new market that management estimates at 600,000–700,000 U.S. patients. Clearance and any resulting sales remain uncertain; the company said CIPN-specific revenue is not included in its 2027 growth outlook.
• Cash, cash equivalents, and marketable securities fell to $7.5 million from $10 million at the end of the prior quarter. The company is evaluating a term-loan refinancing to support its runway, but said it has no agreement in place.

electroCore Price Performance

Shares of NASDAQ ECOR traded down $0.29 during midday trading on Thursday, reaching $8.11. 57,542 shares of the stock were exchanged, compared to its average volume of 87,663. The company has a market capitalization of $73.08 million, a price-to-earnings ratio of -4.90 and a beta of 1.23. The business has a 50-day simple moving average of $9.36 and a two-hundred day simple moving average of $7.75. electroCore has a 12 month low of $4.41 and a 12 month high of $12.70.

Key electroCore News

Here are the key news stories impacting electroCore this week:

• Positive Sentiment: Third-quarter net sales rose 12% year over year to $9.7 million, while net loss narrowed 61% to $1.3 million and adjusted EBITDA loss improved 67%. The $0.13 per-share loss was also better than analyst estimates of roughly $0.26–$0.27. Third-quarter 2026 financial results
• Positive Sentiment: Management outlined a target of 30%–40% revenue growth in 2027 and aims to reach positive adjusted EBITDA by the end of that year. The targets could support investor optimism if the company delivers. 2027 growth and profitability targets
• Neutral Sentiment: electroCore plans to participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 11. The announcement provides an opportunity for investor engagement but does not disclose a new business development. Forum participation announcement
• Negative Sentiment: Quarterly revenue of $9.69 million missed analyst expectations of $10.93 million. The shortfall may temper the positive read-through from sales growth and the narrower loss. Q3 revenue estimate miss

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of electroCore in a research report on Monday, September 21st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $18.00.

Insider Activity

In other electroCore news, CFO Joshua S. Lev sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $9.36, for a total value of $28,080.00. Following the sale, the chief financial officer owned 84,889 shares in the company, valued at $794,561.04. This represents a 3.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Thomas Errico acquired 5,000 shares of electroCore stock in a transaction dated Monday, September 14th. The shares were purchased at an average price of $9.82 per share, with a total value of $49,100.00. Following the acquisition, the director owned 363,904 shares of the company’s stock, valued at approximately $3,573,537.28. This trade represents a 1.39% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders sold a total of 20,000 shares of company stock worth $200,120 in the last three months. Company insiders own 7.80% of the company’s stock.

electroCore Company Profile

electroCore, Inc (NASDAQ: ECOR) is a commercial-stage medical device company focused on bioelectronic medicine and non-invasive vagus nerve stimulation (nVNS). Its technology is designed to stimulate the vagus nerve through the neck without requiring surgery or implanted components.

The company’s primary prescription product is gammaCore, a handheld nVNS device used for the acute treatment of pain associated with migraine and episodic cluster headaches in adults. electroCore also markets consumer-oriented products, including Truvaga, a handheld vagus nerve stimulation device positioned for general wellness applications.